# Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

> **NCT04388215** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 120 (estimated)

## Conditions studied

- Hypertension
- Dyslipidemias

## Interventions

- **DRUG:** CKD-828
- **DRUG:** CKD-828(placebo)
- **DRUG:** D326
- **DRUG:** D326(placebo)
- **DRUG:** D337
- **DRUG:** D337(placebo)
- **DRUG:** D013
- **DRUG:** D013(placebo)

## Key facts

- **NCT ID:** NCT04388215
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-23
- **Primary completion:** 2021-04
- **Final completion:** 2021-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04388215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04388215, "Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04388215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*